Audentes Therapeutics, Inc. announced the acquisition of Cardiogen Sciences, Inc. In conjunction with the acquisition, Dr. Lange has joined the Audentes Therapeutics Board of Directors and Dr. Priori will serve as a Scientific Advisor to Audentes.
Audentes Therapeutics, Inc.
Equities
US05070R1041
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |